Adenovirus News and Research RSS Feed - Adenovirus News and Research

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.
SLU researchers work to prevent several serious infectious diseases

SLU researchers work to prevent several serious infectious diseases

Saint Louis University researchers are attacking influenza on multiple fronts as they search for a universal vaccine that protects people from the flu virus that often mutates year to year with deadly consequences. [More]
Experimental vaccine protects monkeys exposed to Ebola virus

Experimental vaccine protects monkeys exposed to Ebola virus

One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector (called chimp adenovirus type 3 or ChAd3) protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health (NIH) scientists and their collaborators. [More]
Gene therapy may offer significant advantages in prevention of botulism exposure

Gene therapy may offer significant advantages in prevention of botulism exposure

The current method to treat acute toxin poisoning is to inject antibodies, commonly produced in animals, to neutralize the toxin. But this method has challenges ranging from safety to difficulties in developing, producing and maintaining the anti-serums in large quantities. [More]
CHLA ECMO program honored with prestigious Award for Excellence in Life Support

CHLA ECMO program honored with prestigious Award for Excellence in Life Support

The Extracorporeal Membrane Oxygenation program at Children's Hospital Los Angeles has been honored for the third time with the prestigious Award for Excellence in Life Support by the Extracorporeal Life Support Organization, an international group of health care professionals and scientists who evaluate hospital treatment therapies for patients fighting complex cardiac disease and respiratory failure. [More]
International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in West Africa. [More]
NIH to start initial human testing of investigational Ebola vaccine next week

NIH to start initial human testing of investigational Ebola vaccine next week

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. [More]
PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. [More]
PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. [More]
NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. [More]
RAAV/ABAD-DP-6His generates fusion peptide that protects PC12 cells from oxidative stress injury

RAAV/ABAD-DP-6His generates fusion peptide that protects PC12 cells from oxidative stress injury

The effects of Amyloid beta (Aβ)-Aβ-binding alcohol dehydrogenase (ABAD) may exacerbate Alzheimer's disease pathology. [More]
Researchers create universal flu vaccine

Researchers create universal flu vaccine

Researchers at the University of Texas Medical Branch are working to create a universal flu vaccine - one that could eliminate the need for an annual flu shot. [More]
Nanoviricides develops new drug candidates against MERS infection

Nanoviricides develops new drug candidates against MERS infection

... [More]
miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

RNA interference is a process in which RNA molecules inhibit gene expression. This gene silencing process is controlled by RNA-induced silencing complex or RISC and is initiated by small duplex RNA molecules or miRNA that is present inside cell plasma. [More]
NIH study could offer clues for developing new antiviral treatments

NIH study could offer clues for developing new antiviral treatments

A National Institutes of Health study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections. [More]
Researchers develop cardiac tissue from human stem cells to find cures for heart diseases

Researchers develop cardiac tissue from human stem cells to find cures for heart diseases

When it comes to finding cures for heart disease, scientists at Icahn School of Medicine at Mount Sinai are working to their own beat. They may have developed a tissue model for the human heart that can bridge the gap between animal models and human clinical trial patients. [More]
Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

In recognition of his seminal work on adenoviral vectors, which accelerated the translation of gene therapy from the research laboratory to the clinic, Ronald G. Crystal, MD (Weill Cornell Medical College, Cornell University, New York City), has received a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Scientists develop tissue model for human heart

Scientists develop tissue model for human heart

When it comes to finding cures for heart disease scientists are working to their own beat. That's because they may have finally developed a tissue model for the human heart that can bridge the gap between animal models and human patients. [More]
Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”. [More]
New form of gene therapy shows promising outcomes for "bubble boy" disease

New form of gene therapy shows promising outcomes for "bubble boy" disease

Researchers reported promising outcomes data for the first group of boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a fatal genetic immunodeficiency also known as "bubble boy" disease, who were treated as part of an international clinical study of a new form of gene therapy. The mechanism used to deliver the gene therapy is designed to prevent the serious complication of leukemia that arose a decade ago in a similar trial in Europe, when one-quarter of boys treated developed the blood cancer. [More]
Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

... [More]